Clay Siegall, The Man With Revolutionary Technology In Treating Cancer

Clay B. Siegall is a man who’s achieved a lot in the field of medicine. He co-founded Seattle Genetics in the year 1998. The company is a drug research and development company that is built on the principle of providing medical solutions in the field of oncology. The company aims at producing that are a particular target for cancer cells without destroying healthy body cells.

Clay Siegall resolve to provide solutions to cancer patients began when he was 19 years old. He helplessly watched his father succumb to cancer, and that is when he knew that the field of oncology was grappling with limited resources to fight cancer. He is the current President, Chief Executive Officer and Chairman of the Board at Seattle Genetics.

His professional career in medicine started after he earned a Bachelor of Science Degree in Zoology from the University of Maryland. Later, he advanced is knowledge in the field of genetics by earning a Ph.D. in Genetics from the University of George Washington. Clay Siegall has 70 publications to his name and holds 15 patents. He also sits at Ultragenyx Pharmaceutical, Alder BioPharmaceuticals, and Washington Roundtable Boards of Directors.

Lately, cancer cases have been on the rise necessitating more research and involvement in tackling the disease. Seattle Genetics works to provide more effective drugs with limited side effects to patients. Clay Siegall believes building a network of smart people from which practical solutions can be born.

Clay Siegall has led Seattle Genetics in developing antibody-drug conjugates (ADCs), a first in the field of oncology. Collaborating with other industry players such as GeneTech (Roche), AbbVie, GlaxoSmithKline and Pfizer, the company has signed multiple strategic licenses for its drug development technology (ADC). The partnerships have generated more than $350 million to date.

Seattle Genetics is a publicly listed company having carried out a successful public offering in the year 2001. The public offering together with other private sources of funding has enabled the company to secure over $1.2 billion in financial muscle.

Through technology, innovation and strategic partnership that are the main pillars guiding the company, Clay Siegall hopes to create an impact as far as the fight against cancer is concerned.